Accessibility Menu
Novartis Ag logo

Novartis Ag(OTC) NVSEF

Market Cap$299.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+357%
5 Year+86%
1 Year+14%
1 Month-9%
$145.01
+0.00%
+0.00Today
Novartis Ag last closing stock price
MetricPriceDate
Last closeUSD 145.012026-08-31
Novartis Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.36%USD 163.602026-08-24
1 month-8.52%USD 158.522026-07-31
3 month+0.61%USD 144.142026-06-02
Year to date+8.36%USD 133.822025-12-31
1 year+14.4%USD 126.762025-08-29
3 year+62.19%USD 89.412023-09-01
5 year+85.97%USD 77.982021-08-31
Since inception+357.25%USD 35.782003-06-26

Novartis Ag Financials at a Glance

Market Cap

$299.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$54.75B

Net Income (TTM)

$12.64B

EPS (TTM)

$6.63

P/E Ratio

24.54

Dividend

$4.74

Beta (Volatility)

0.06 (Low)

Price

$145.01

Volume

385

Open

$145.01

Previous Close

$145.01

Daily Range

$145.01 - $145.01

52-Week Range

$118.02 - $171.29

Estimated Earnings Date

Oct 27, 2026

NVSEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novartis Ag

Novartis AG is a global pharmaceutical enterprise based in Basel, Switzerland, focused on the entire lifecycle of healthcare products. Established in 1996, the company operates through two main divisions: Innovative Medicines and Sandoz, providing advanced prescription medications and a wide range of generic and biosimilar products.

Products and Services
  • Innovative Medicines segment offers advanced prescription medications across various therapeutic areas
  • Sandoz specializes in generic and biosimilar products, including antibiotics and active pharmaceutical ingredients
  • Strategic collaborations for drug development, including partnerships with Alnylam Pharmaceuticals and Kura Oncology
Growth Outlook
  • Recent quarterly revenue of $14.1 billion shows strong market demand
  • Net income for Q2 2026 reached $3.19 billion, indicating robust profitability
  • Continued investment in R&D, with $2.7 billion spent in Q2 2026 to drive innovation
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.5 billion reflects consistent growth
  • Net profit margin of 23.09% demonstrates effective cost management
  • Dividend yield of 2.90% offers attractive returns to shareholders
Novartis AG stands out in the pharmaceutical industry due to its comprehensive approach to healthcare, from research and development to commercialization. The company's commitment to innovation is evident in its significant investment in R&D, which supports the development of new therapies across various therapeutic areas. The recent financial performance highlights a strong revenue base and profitability, making it an appealing option for potential investors. The combination of a solid dividend yield and a focus on growth through strategic partnerships further enhances its attractiveness in the healthcare sector.
AI Generated • Aug 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,267

CEO

Vasant Narasimhan, MD

Website

www.novartis.com

Headquarters

Basel, BS 4056, CH

NVSEF Financials

Key Financial Metrics (TTM)

Gross Margin

74.29%

Operating Margin

29.86%

Net Income Margin

23.09%

Return on Equity

29.64%

Return on Capital

21.41%

Return on Assets

10.34%

Earnings Yield

4.07%

Dividend Yield

2.90%

Payout Ratio

67.77%

Stock Overview

Market Cap

$299.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

385

Avg. Volume

37.13K

Financials (TTM)

Gross Profit

$40.67B

Operating Income

$16.57B

EBITDA

$22.69B

Operating Cash Flow

$18.06B

Capital Expenditure

-$2.11B

Free Cash Flow

$15.96B

Cash & ST Invst.

$7.67B

Total Debt

$48.91B

Novartis Ag Performance Analysis

Novartis Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,206,000,000-18.2%
20232023-12-31USD 45,440,000,0007.7%
20242024-12-31USD 50,317,000,00010.7%
20252025-12-31USD 54,532,000,0018.4%
Novartis Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.2%
Q42025-12-31-6.4%
Q12026-03-31-4.4%
Q22026-06-309.6%
Novartis Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.17-70.2%
20232023-12-31USD 7.10124.2%
20242024-12-31USD 5.87-17.3%
20252025-12-31USD 7.1521.9%
Novartis Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.9%
Q42025-12-31-37.0%
Q12026-03-3128.6%
Q22026-06-303.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$14.09B

-5.0%

Gross Profit

$10.49B

-8.9%

Gross Margin

74.47%

N/A

Market Cap

$299.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.98M

N/A

Employees

75,267

N/A

Net Income

$3.19B

-21.0%

EBITDA

$5.80B

-4.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.67B

+9.6%

Total Debt

$48.91B

+49.9%

Accounts Receivable

$9.83B

+7.2%

Inventory

$6.21B

-1.6%

Long Term Debt

$39.07B

+62.4%

Short Term Debt

$9.84B

+14.8%

Return on Assets

10.34%

N/A

Return on Invested Capital

18.07%

N/A

Free Cash Flow

$5.43B

-11.1%

Operating Cash Flow

$5.74B

-13.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHHVFRoche Holding AG
$428.92-5.33%
RHHBYRoche Holding AG
$53.70-2.70%
RHHBFRoche Holding AG
$453.79-0.60%
NONOFNovo Nordisk A/S
$45.25+0.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About NVSEF

What is the current price of Novartis Ag?

Novartis Ag is trading at $145.01 per share.

What is the 52-week range for Novartis Ag?

Over the past 52 weeks, Novartis Ag has traded between $118.02 and $171.29.

How much debt does Novartis Ag have?

As of the most recent reporting period, Novartis Ag reported total debt of $49.01B.

How much cash does Novartis Ag have on hand?

Novartis Ag reported $7.62B in cash and cash equivalents in its most recent financial results.

What is Novartis Ag’s dividend yield?

Novartis Ag currently has a dividend yield of 2.90%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services